retatrutide type 2 diabetes trial results 2024 2025 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of Retatrutide produces up to 30.3%
Pay in 4 interest-free payments of $6.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2









![Zepbound Lawsuit [2026]](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Zepbound-Lawsuit-768x384.jpg)



![Mounjaro Lawsuit [2026 Update]](https://www.torhoermanlaw.com/wp-content/uploads/2026/05/Mounjaro-Lawsuit.jpg)













